Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · January 05, 2022

Measurable Residual Disease Response in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
J. Clin. Oncol 2021 Dec 15;[EPub Ahead of Print], KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, JS Garcia, CD DiNardo, V Vorobyev, NS Fracchiolla, SP Yeh, JH Jang, M Ozcan, K Yamamoto, A Illes, Y Zhou, M Dail, B Chyla, J Potluri, H Döhner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading